Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.76 |
| ▸ | TNKS | O95271 | 1/20 | 0.69 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.69 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.69 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.69 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.69 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.69 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 2/20 | 0.62 |
| ▸ | CRHBP | P24387 | 1/20 | 0.62 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.62 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 3/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.60 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.54 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | AHR | P35869 | 1/20 | 0.52 |
| ▸ | PARP1 | P09874 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15054453 | 0.90 | TSHR (0.73) | KDM4ETNKSPARP15PARP14PARP10 | |
| SCHEMBL177838 | 0.87 | KDM4E (1.00) | KDM4EFFAR1ALDH1A1CRHBPCRHR2 | |
| SCHEMBL11601386 | 0.85 | KDM4E (0.76) | KDM4ETNKSPARP15PARP14PARP10 | |
| SCHEMBL668647 | 0.85 | FFAR1 (0.71) | KDM4EFFAR1ALDH1A1CRHBPCRHR2 | |
| SCHEMBL8339732 | 0.84 | TSHR (0.79) | KDM4EPARP15PARP14PARP10ALDH1A1 | |
| Diphenylether SCHEMBL6859636 | 0.83 | TSHR (0.71) | KDM4ETNKSPARP15PARP14PARP10 | |
| SCHEMBL31504019 | 0.83 | KDM4E (0.72) | KDM4EFFAR1ALDH1A1CRHBPCRHR2 | |
| SCHEMBL6631040 | 0.82 | PARP10 (1.00) | TNKSPARP15PARP14PARP10TNKS2 | |
| SCHEMBL27188054 | 0.82 | ALDH1A1 (0.77) | KDM4EFFAR1ALDH1A1TSHRCRHBP | |
| SCHEMBL7632953 | 0.82 | ALDH1A1 (0.77) | KDM4EFFAR1ALDH1A1TSHRCRHBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025102082-A1 | CARBOCYCLIC AND HETEROCYCLIC STAT3 INHIBITOR COMPOSITIONS AND METHODS | ALTAY THERAPEUTICS, INC. (US) | 2025-05-15 | — | — | WO | disclosed |
| US-20140329866-A1 | OMEGA-CARBOXYARL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | BAYER HEALTHCARE LLC (US) | 2014-11-06 | — | — | US | disclosed |
| US-8841330-B2 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC (US) | 2014-09-23 | — | — | US | disclosed |
| EP-1636585-B2 | DIARYL UREAS WITH KINASE INHIBITING ACTIVITY | BAYER HEALTHCARE LLC (US) | 2012-06-13 | — | — | EP | disclosed |
| US-20120142742-A1 | OMEGA-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | BAYER HEALTHERCARE LLC (US) | 2012-06-07 | — | — | US | disclosed |
| EP-2298311-B1 | w-Carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors | BAYER HEALTHCARE LLC (US) | 2012-05-09 | — | — | EP | disclosed |
| US-8124630-B2 | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC (US) | 2012-02-28 | — | — | US | disclosed |
| US-20120040986-A1 | OMEGA CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | RIEDL BERND (DE) | 2012-02-16 | — | — | US | disclosed |
| EP-1158985-B1 | OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS | BAYER HEALTHCARE LLC (US) | 2011-12-28 | — | — | EP | disclosed |
| EP-2386545-A1 | Heteroaryl ureas containing nitrogen hetero-atoms as P38 kinase inhibitors | Bayer Healthcare LLC (US) | 2011-11-16 | — | — | EP | disclosed |
| EP-1140840-A1 | -G(V)-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | Bayer Corporation (US) | 2001-10-10 | — | — | EP | disclosed |
| US-20010027202-A1 | Omega-carboxyaryl substituted disphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC | 2001-10-04 | — | — | US | disclosed |
| US-20010016659-A1 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC | 2001-08-23 | — | — | US | disclosed |
| US-20010011135-A1 | Omega-carboxyaryl subsituted diphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC | 2001-08-02 | — | — | US | disclosed |
| US-20010011136-A1 | omega-carboxyyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC | 2001-08-02 | — | — | US | disclosed |
| WO-2000041698-A1 | φ-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS | BAYER CORPORATION (US) | 2000-07-20 | — | — | WO | disclosed |
| WO-2000042012-A1 | φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | BAYER CORPORATION (US) | 2000-07-20 | — | — | WO | disclosed |
| EP-0636025-A4 | COMPOUNDS USEFUL FOR TREATING ALLERGIC OR INFLAMMATORY DISEASES. | — | 1995-02-22 | — | — | EP | disclosed |
| EP-0636025-A1 | COMPOUNDS USEFUL FOR TREATING ALLERGIC OR INFLAMMATORY DISEASES | SMITHKLINE BEECHAM CORPORATION (US) | 1995-02-01 | — | — | EP | disclosed |
| WO-1993019750-A1 | COMPOUNDS USEFUL FOR TREATING ALLERGIC OR INFLAMMATORY DISEASES | SMITHKLINE BEECHAM CORPORATION (US) | 1993-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010011135-A1 | Omega-carboxyaryl subsituted diphenyl ureas as raf kinase inhibitors | BRAF, RAF1, ARAF | KDM4E 1572/4885TNKS 901/4885PARP15 2888/4885 |
| US-20010011136-A1 | omega-carboxyyaryl substituted diphenyl ureas as raf kinase inhibitors | BRAF, ARAF, RAF1 | KDM4E 1326/4885TNKS 304/4885PARP15 3614/4885 |
| US-20010016659-A1 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BRAF, RAF1, ARAF | KDM4E 1426/4885TNKS 603/4885PARP15 2941/4885 |
| US-20140329866-A1 | OMEGA-CARBOXYARL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | KDM4E 1407/4885TNKS 520/4885PARP15 3373/4885 |
| US-20010027202-A1 | Omega-carboxyaryl substituted disphenyl ureas as raf kinase inhibitors | BRAF, NRAS, ARAF | KDM4E 2089/4885TNKS 798/4885PARP15 2198/4885 |
| US-20120040986-A1 | OMEGA CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | BRAF, NRAS, RAF1 | KDM4E 1477/4885TNKS 803/4885PARP15 3241/4885 |
| US-20120142742-A1 | OMEGA-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | KDM4E 1426/4885TNKS 603/4885PARP15 2941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.